Kenichi Miyamoto - Publications

First-line therapy for high-risk people with chronic lymphocytic leukemia: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: October 30, 2024

HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1).

Journal: Cancer science

Published: May 26, 2021

Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.

Journal: Japanese journal of clinical oncology

Published: June 03, 2020

Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: May 31, 2020

Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma.

Journal: International journal of clinical oncology

Published: May 02, 2020

Evaluation of the representativeness and generalizability of Japanese clinical trials for localized rectal/colon cancer: Comparing participants in the Japan Clinical Oncology Group study with patients in Japanese registries.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: March 23, 2020

Vascular adverse events of ponatinib during treatment of Philadelphia chromosome-positive leukemia: a retrospective single-institution analysis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: January 07, 2020

Hairy cell leukemia complicated by bone marrow necrosis following cladribine administration

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 09, 2019

Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial).

Journal: Japanese journal of clinical oncology

Published: May 22, 2019

Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.

Journal: International journal of clinical oncology

Published: April 14, 2019

Study risk assessment of Japan Clinical Oncology Group (JCOG) clinical trials using the European Organisation for Research and Treatment of Cancer (EORTC) study risk calculator.

Journal: Japanese journal of clinical oncology

Published: December 11, 2018

Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.

Journal: International journal of hematology

Published: July 30, 2018